Bryn Mawr Capital Management LLC Has $1.03 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Bryn Mawr Capital Management LLC trimmed its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 72.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,741 shares of the company’s stock after selling 41,932 shares during the period. Bryn Mawr Capital Management LLC’s holdings in AstraZeneca were worth $1,031,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. New York State Common Retirement Fund raised its stake in shares of AstraZeneca by 7.4% in the 4th quarter. New York State Common Retirement Fund now owns 133,043 shares of the company’s stock valued at $8,717,000 after purchasing an additional 9,124 shares during the period. Davidson Investment Advisors grew its holdings in shares of AstraZeneca by 0.9% during the fourth quarter. Davidson Investment Advisors now owns 227,775 shares of the company’s stock worth $14,924,000 after buying an additional 2,096 shares in the last quarter. Buckingham Capital Management Inc. raised its position in AstraZeneca by 1.3% in the 4th quarter. Buckingham Capital Management Inc. now owns 197,505 shares of the company’s stock valued at $12,941,000 after buying an additional 2,501 shares during the last quarter. Kestra Investment Management LLC bought a new stake in AstraZeneca in the 4th quarter valued at approximately $173,000. Finally, Atria Wealth Solutions Inc. boosted its position in AstraZeneca by 16.2% during the 4th quarter. Atria Wealth Solutions Inc. now owns 50,035 shares of the company’s stock worth $3,278,000 after acquiring an additional 6,970 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

Shares of AZN stock opened at $74.56 on Friday. The company has a fifty day moving average price of $68.60 and a two-hundred day moving average price of $73.30. AstraZeneca PLC has a one year low of $62.75 and a one year high of $87.68. The stock has a market cap of $231.22 billion, a P/E ratio of 32.99, a P/E/G ratio of 1.44 and a beta of 0.46. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Monday, March 24th. Investors of record on Friday, February 21st will be paid a $1.03 dividend. This represents a yield of 2%. The ex-dividend date is Friday, February 21st. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s dividend payout ratio is 43.36%.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent research reports. Morgan Stanley started coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, UBS Group raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.